Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

被引：9

作者：

Al-Sawaf, Othman ^{[1
]}

Seymour, John F. ^{[2
]}

Kater, Arnon P. ^{[3
]}

Fischer, Kirsten ^{[1
]}

机构：

[1] Univ Hosp, Dept Internal Med, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Gleueler Str 176, D-50935 Cologne, Germany

[2] Univ Melbourne, Dept Hematol, Peter MacCallum Canc Ctr, Royal Melbourne Hosp, 305 Grattan St, Melbourne, Vic 3000, Australia

[3] Univ Amsterdam, Dept Hematol, Canc Ctr Amsterdam, Lymphoma & Myeloma Res Ctr Amsterdam LYMMCARE,Ams, Amsterdam, Netherlands

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 04期

关键词：

MRD; Minimal residual disease; CLL; Chronic lymphocytic leukemia; Targeted agents; Chemoimmunotherapy; Fixed-duration therapy; PREVIOUSLY UNTREATED PATIENTS; OPEN-LABEL; FOLLOW-UP; 1ST-LINE TREATMENT; FLOW-CYTOMETRY; INDEPENDENT PREDICTOR; CELL TRANSPLANTATION; PLUS CHLORAMBUCIL; CLL; RITUXIMAB;

D O I：

10.1016/j.hoc.2021.03.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hospital, German CLL Study Group, Gleueler Strasse 176, 50935 Cologne, Germany; b Department of Hematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, 305 Grattan Street, Melbourne, Victoria 3000, Australia; cDepartment of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Research Center Amsterdam (LYMMCARE), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands * Corresponding author. Department of Hematology, D3-221.1, Amsterdam University Medical Centers, Location AMC, Meibergdreef 9, Amsterdam 1105AZ, the Netherlands.

引用

页码：775 / 791

页数：17

共 81 条

[1] Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study [J].

Ahn, Inhye E. ;

Farooqui, Mohammed Z. H. ;

Tian, Xin ;

Valdez, Janet ;

Sun, Clare ;

Soto, Susan ;

Lotter, Jennifer ;

Housel, Stephanie ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance M. ;

Maric, Irina ;

Calvo, Katherine R. ;

Nierman, Pia ;

Hughes, Thomas E. ;

Saba, Nakhle S. ;

Marti, Gerald E. ;

Pittaluga, Stefania ;

Herman, Sarah E. M. ;

Niemann, Carsten U. ;

Pedersen, Lone B. ;

Geisler, Christian H. ;

Childs, Richard ;

Aue, Georg ;

Wiestner, Adrian .

BLOOD, 2018, 131 (21) :2357-2366

[2]

Al-Sawaf O, 2020, LANCET ONCOL, V21, P1188, DOI 10.1016/S1470-2045(20)30443-5

[3] High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia [J].

Al-Sawaf, Othman ;

Lilienweiss, Esther ;

Bahlo, Jasmin ;

Robrecht, Sandra ;

Fink, Anna-Maria ;

Patz, Michaela ;

Tandon, Maneesh ;

Jiang, Yanwen ;

Schary, William ;

Ritgen, Matthias ;

Tausch, Eugen ;

Stilgenbauer, Stephan ;

Eichhorst, Barbara ;

Fischer, Kirsten ;

Hallek, Michael ;

Kreuzer, Karl-Anton .

BLOOD, 2020, 135 (11) :866-870

[4] Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis [J].

Boettcher, S. ;

Stilgenbauer, S. ;

Busch, R. ;

Brueggemann, M. ;

Raff, T. ;

Pott, C. ;

Fischer, K. ;

Fingerle-Rowson, G. ;

Doehner, H. ;

Hallek, M. ;

Kneba, M. ;

Ritgen, M. .

LEUKEMIA, 2009, 23 (11) :2007-2017

[5] The Role of Minimal Residual Disease Measurements in the Therapy for CLL Is It Ready for Prime Time? [J].

Boettcher, Sebastian ;

Hallek, Michael ;

Ritgen, Matthias ;

Kneba, Michael .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (02) :267-+

[6] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Fischer, Kirsten ;

Stilgenbauer, Stephan ;

Busch, Raymonde M. ;

Fingerle-Rowson, Guenter ;

Fink, Anna Maria ;

Buehler, Andreas ;

Zenz, Thorsten ;

Wenger, Michael Karl ;

Mendila, Myriam ;

Wendtner, Clemens-Martin ;

Eichhorst, Barbara F. ;

Doehner, Hartmut ;

Hallek, Michael J. ;

Kneba, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :980-988

[7] Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Dreger, Peter .

BLOOD REVIEWS, 2011, 25 (02) :91-96

[8] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation [J].

Böttcher, S ;

Ritgen, M ;

Pott, C ;

Brüggemann, M ;

Raff, T ;

Stilgenbauer, S ;

Döhner, H ;

Dreger, P ;

Kneba, M .

LEUKEMIA, 2004, 18 (10) :1637-1645

[9] Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL [J].

Brander, Danielle M. ;

Seymour, John F. ;

Kipps, Thomas J. ;

Ma, Shuo ;

Anderson, Mary Ann ;

Choi, Michael Y. ;

Humphrey, Kathryn ;

Al Masud, Abdullah ;

Nandam, Ruby ;

Jacobson, Amanda ;

Roberts, Andrew W. .

BLOOD, 2019, 134

[10] Circulating cell-free DNA in hematological malignancies [J].

Buedts, Lieselot ;

Vandenberghe, Peter .

HAEMATOLOGICA, 2016, 101 (09) :997-999

← 1 2 3 4 5 6 7 8 9 →